ClinicalTrials.gg
CompletedNCT01474083Updated Sep 13, 2013

A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

A Phase 1/2 interventional study of GK1-399 (formerly TTP399) and GK1-399 (formerly TTP399) in Type 2 Diabetes Mellitus, sponsored by vTv Therapeutics. Completed at 11 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-09-13.

Sponsored by vTv Therapeutics · Phase 1/2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
870th of 2,957
248 · median 90
Started
2011
with 151 others
Phase 1/2
40 of 3,304
3 open now
Registered
1,192nd of 3,304
by date

Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 870th largest by enrollment of the 2,957 interventional ones that give a count, is one of 152 that started in 2011, is one of 40 in phase 1/2, and was the 1,192nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

338 more — sign in →

All 343 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this trial is to study the drug levels and biomarkers in the body and the safety of an investigational drug (GK1-399) in patients with Type 2 diabetes. Patients in the study will receive placebo for 1 week followed by 1 of 4 treatments for 6 weeks. One of the 4 treatments will be placebo, which does not contain an active ingredient. The study participation includes in-patient and out-patient days.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Type 2 diabetes mellitus
  • pharmacokinetics
  • pharmacodynamics
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be male or female, aged 18 through 75 years at screening.
  • Have a diagnosis of Type 2 Diabetes Mellitus (T2DM)
  • On a stable dose of background medication for the treatment of diabetes
  • (BMI) between 20-40 kg/m2 (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Subjects with type 1 diabetes, heart attack or stroke in the past 6 months, uncontrolled blood pressure, significant kidney disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
248 participants (actual)

Study arms

  • Experimental
    GK1-399, low dose

    Drug: GK1-399 (formerly TTP399)

  • Experimental
    GK1-399, high dose, once per day

    Drug: GK1-399 (formerly TTP399)

  • Experimental
    GK1-399, high dose, twice per day

    Drug: GK1-399 (formerly TTP399)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugGK1-399 (formerly TTP399)

    Treatment A: GK1-399 200 mg. Oral administration, twice per day.

  • DrugGK1-399 (formerly TTP399)

    Treatment B: GK1-399 800 mg. Oral administration, once per day.

  • DrugGK1-399 (formerly TTP399)

    Treatment C: GK1-399 800 mg. Oral administration, twice per day.

  • DrugPlacebo

    Dose-matched placebo. Oral administration.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameters of GK1-399 from plasma concentrations

    Area under the plasma concentration verses time curve from time 0 to the end of the dosing interval, maximum plasma concentration

    Time frame: 52 time points over a 6 week period

Secondary outcomes

  1. Pharmacodynamic parameters of plasma glucose

    Fasting plasma glucose and postprandial plasma glucose

    Time frame: 52 time points over a 6 week period

07

Study locations

11 sites
  • Forest Investigative Site 009
    Little Rock, Arkansas 72211, United States
  • Forest Investigative Site 006
    Chula Vista, California 91911, United States
  • Forest Investigative Site 002
    Deland, Florida 32720, United States
  • Forest Investigative Site 001
    Miami, Florida 33014, United States
  • Forest Investigative Site 010
    Overland Park, Kansas 66212, United States
  • Forest Investigative site 011
    St. Paul, Minnesota 55114, United States
  • Forest Investigative Site 005
    Springfield, Missouri 65802, United States
  • Forest Investigative Site 003
    Neptune, New Jersey 07753, United States
  • Forest Investigative Site 008
    Willingboro, New Jersey 08046, United States
  • Forest Investigative Site 007
    New York, New York 10029, United States
  • Forest Investigative Site 004
    San Antonio,, Texas 78209, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Aug 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2011
First posted
Nov 18, 2011
Start
Nov 2011
Primary completionActual
Aug 2012
CompletionActual
Sep 2012
Results delay requested
Oct 3, 2012
Last update
Sep 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01474083
Lead sponsor
vTv Therapeutics
Responsible party
Sponsor
First posted
Nov 18, 2011
Start date
Nov 2011
Primary completion
Aug 2012
Completion
Sep 2012
Last update
Sep 13, 2013

Study contacts

Aaron Burstein, Pharm.D.
study director · TransTech Pharma, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion